Literature DB >> 24584913

How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0.

Maarten Boers1, John R Kirwan, Laure Gossec, Philip G Conaghan, Maria-Antonietta D'Agostino, Clifton O Bingham, Peter M Brooks, Robert Landewé, Lyn March, Lee Simon, Jasvinder A Singh, Vibeke Strand, George A Wells, Peter Tugwell.   

Abstract

OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) initiative works to develop core sets of outcome measures for trials and observational studies in rheumatology. At the OMERACT 11 meeting, substantial time was devoted to discussing a conceptual framework and a proposal for a more explicit working process to develop what we now propose to term core outcome measurement sets, collectively termed "OMERACT Filter 2.0."
METHODS: Preconference work included a literature review, and discussion of preliminary proposals through face-to-face discussions and Internet-based surveys with people within and outside rheumatology. At the conference, 5 interactive sessions comprising plenary and small-group discussions reflected on the proposals from the viewpoint of previous and ongoing OMERACT work. These considerations were brought together in a final OMERACT presentation seeking consensus agreement for the Filter 2.0 framework.
RESULTS: After debate, clarification, and agreed alterations, the final proposal suggested all core sets should contain at least 1 measurement instrument from 3 Core Areas: Death, Life Impact, and Pathophysiological Manifestations, and preferably 1 from the area Resource Use. The process of core set development for a health condition starts by selecting core domains within the areas ("core domain set"). This requires literature searches, involvement (especially of patients), and at least 1 consensus process. Next, developers select at least 1 applicable measurement instrument for each core domain. Applicability refers to the original OMERACT Filter and means that the instrument must be truthful (face, content, and construct validity), discriminative (between situations of interest) and feasible (understandable and with acceptable time and monetary costs). Depending on the quality of the instruments, participants formulate either a preliminary or a final "core outcome measurement set." At final vote, 96% of participants agreed "The proposed overall framework for Filter 2.0 is a suitable basis on which to elaborate a Filter 2.0 Handbook."
CONCLUSION: Within OMERACT, Filter 2.0 has made established working processes more explicit and includes a broadly endorsed conceptual framework for core outcome measurement set development.

Entities:  

Keywords:  CLINICAL TRIALS; CORE OUTCOME SETS; OMERACT FILTER; OUTCOME AND PROCESS ASSESSMENT

Mesh:

Year:  2014        PMID: 24584913     DOI: 10.3899/jrheum.131314

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  31 in total

Review 1.  More than Just Minutes of Stiffness in the Morning: Report from the OMERACT Rheumatoid Arthritis Flare Group Stiffness Breakout Sessions.

Authors:  Ana-Maria Orbai; Serena Halls; Sarah Hewlett; Susan J Bartlett; Amye L Leong; Clifton O Bingham
Journal:  J Rheumatol       Date:  2015-03-01       Impact factor: 4.666

2.  Physician-Centered Outcomes for Skin Cancer Treatment: A Single-Day Modified Delphi Process to Assess the Importance of Themes in Skin Cancer Management.

Authors:  Anthony M Rossi; Joseph Sobanko; Naomi Lawrence; Jeremy Bordeaux; Todd Cartee; Eric S Armbrecht; Anit Behera; Christian L Baum; Murad Alam; Ian A Maher
Journal:  Dermatol Surg       Date:  2019-07       Impact factor: 3.398

3.  Responsiveness and Minimally Important Differences for 4 Patient-Reported Outcomes Measurement Information System Short Forms: Physical Function, Pain Interference, Depression, and Anxiety in Knee Osteoarthritis.

Authors:  Augustine C Lee; Jeffrey B Driban; Lori Lyn Price; William F Harvey; Angie Mae Rodday; Chenchen Wang
Journal:  J Pain       Date:  2017-05-10       Impact factor: 5.820

4.  Updating the OMERACT filter: core areas as a basis for defining core outcome sets.

Authors:  John R Kirwan; Maarten Boers; Sarah Hewlett; Dorcas Beaton; Clifton O Bingham; Ernest Choy; Philip G Conaghan; Maria-Antonietta D'Agostino; Maxime Dougados; Daniel E Furst; Francis Guillemin; Laure Gossec; Désirée M van der Heijde; Margreet Kloppenburg; Tore K Kvien; Robert B M Landewé; Sarah L Mackie; Eric L Matteson; Philip J Mease; Peter A Merkel; Mikkel Ostergaard; Lesley Ann Saketkoo; Lee Simon; Jasvinder A Singh; Vibeke Strand; Peter Tugwell
Journal:  J Rheumatol       Date:  2014-03-15       Impact factor: 4.666

5.  Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report.

Authors:  Susan J Bartlett; Skye P Barbic; Vivian P Bykerk; Ernest H Choy; Rieke Alten; Robin Christensen; Alfons den Broeder; Bruno Fautrel; Daniel E Furst; Francis Guillemin; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; Pamela Montie; Christoph Pohl; Marieke Scholte Voshaar; Thasia G Woodworth; Clifton O Bingham
Journal:  J Rheumatol       Date:  2017-08-15       Impact factor: 4.666

Review 6.  Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Authors:  Gulen Hatemi; Peter A Merkel; Vedat Hamuryudan; Maarten Boers; Haner Direskeneli; Sibel Z Aydin; Hasan Yazici
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

7.  OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions.

Authors:  Karine Toupin-April; Jennifer L Barton; Liana Fraenkel; Alexa Meara; Linda C Li; Peter Brooks; Maarten de Wit; Dawn Stacey; France Légaré; Beverley Shea; Anne Lyddiatt; Cathie Hofstetter; Robin Christensen; Marieke Scholte Voshaar; Maria E Suarez-Almazor; Annelies Boonen; Tanya Meade; Lyn March; Janet Elizabeth Jull; Willemina Campbell; Rieke Alten; Suvi Karuranga; Esi M Morgan; Ayano Kelly; Jessica Kaufman; Sophie Hill; Lara J Maxwell; Dorcas Beaton; Yasser El-Miedany; Shikha Mittoo; Susan J Bartlett; Jasvinder A Singh; Peter S Tugwell
Journal:  J Rheumatol       Date:  2019-02-01       Impact factor: 4.666

8.  Current status of outcome measure development in vasculitis.

Authors:  Peter A Merkel; Sibel Z Aydin; Maarten Boers; Christina Cornell; Haner Direskeneli; Don Gebhart; Gulen Hatemi; Raashid Luqmani; Eric L Matteson; Nataliya Milman; Joanna Robson; Philip Seo; Gunnar Tomasson
Journal:  J Rheumatol       Date:  2014-01-15       Impact factor: 4.666

9.  American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Hermine I Brunner; Michael J Holland; Michael W Beresford; Stacy P Ardoin; Simone Appenzeller; Clovis A Silva; Francisco Flores; Beatrice Goilav; Pinar Ozge Avar Aydin; Scott E Wenderfer; Deborah M Levy; Angelo Ravelli; Raju Khubchandani; Tadej Avcin; Marisa S Klein-Gitelman; Nicolino Ruperto; Brian M Feldman; Jun Ying
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-05       Impact factor: 4.794

10.  American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Hermine I Brunner; Michael Holland; Michael W Beresford; Stacy P Ardoin; Simone Appenzeller; Clovis A Silva; Francisco Flores; Beatrice Goilav; Scott E Wenderfer; Deborah M Levy; Angelo Ravelli; Raju Khunchandani; Tadej Avcin; Marisa S Klein-Gitelman; Brian M Feldman; Nicolino Ruperto; Jun Ying
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-04-25       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.